Cytek Biosciences, Inc. (CTKB) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Cytek Biosciences is a cell analysis solutions company leveraging Full Spectrum Profiling (FSP) technology. The company operates as a single reportable segment, manufacturing instruments (Cytek Aurora, Northern Lights, Amnis, Guava) and providing reagents and services globally. The company is a large accelerated filer with 127.9 million shares of common stock outstanding as of October 31, 2025.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $52.3 million | $51.5 million | $139.4 million | $143.0 million |
| Gross Profit | $27.6 million | $29.0 million | $71.6 million | $77.5 million |
| Gross Margin | 53% | 56% | 51% | 54% |
| Net Loss | $(5.5) million | $0.9 million (Income) | $(22.5) million | $(15.7) million |
| Diluted EPS | $(0.04) | $0.01 | $(0.18) | $(0.12) |
| Cash & Equivalents | $93.3 million | $98.7 million | $93.3 million | $162.3 million |
| Marketable Securities | $168.5 million | $179.1 million | $168.5 million | $179.1 million |
| Total Debt | $0.7 million | $1.1 million | $0.7 million | $1.1 million |
Material Changes vs. Prior Period
- Revenue Mix: Product revenue decreased 4% QoQ and 10% YTD, driven by lower instrument sales in EMEA and the U.S. Service revenue increased 19% QoQ and 20% YTD due to a larger installed base.
- Operating Expenses: General and Administrative (G&A) expenses surged 47% QoQ and 25% YTD. This increase was primarily due to ongoing patent litigation expenses and a $0.7 million non-recurring charge for the write-off of deferred offering costs related to an expired "at-the-market" program.
- Profitability: The company reported a net loss of $5.5 million in Q3 2025, compared to net income of $0.9 million in Q3 2024. Gross margins compressed due to higher service labor/travel costs and product overhead/tariff costs.
- Cash Flow: Operating cash flow turned negative, using $3.9 million YTD 2025 compared to providing $23.4 million YTD 2024, largely due to increased inventory levels ($7.3 million increase) and the net loss.
Guidance, Outlook, and Risks
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses in the control environment and control activities (specifically regarding IT general controls and journal entry reviews). A remediation plan is underway.
- Legal Proceedings: The company is defending a patent infringement lawsuit filed by Beckman Coulter, Inc. in August 2024. Trial is scheduled for August 2026. Additionally, the company has a long-standing settlement liability with Becton, Dickinson and Company (BD) totaling $10.3 million.
- Share Repurchases: Under a program approved in December 2024, the company repurchased 3.3 million shares for $15.1 million YTD 2025. Approximately $35.0 million remains authorized under this program, which expires December 31, 2025.
- Regulatory & Tax: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 restored immediate deductions for domestic R&D, impacting the company's effective tax rate and deferred tax assets. New U.S. export controls announced in January 2025 may impact sales to China.
Investor Verification Checklist
- Remediation of Material Weaknesses: Verify the progress of the remediation plan for internal control deficiencies identified in the financial reporting process.
- Beckman Coulter Litigation: Monitor the status of the patent infringement lawsuit and potential financial exposure or operational restrictions.
- Export Control Impact: Assess the actual impact of new U.S. export controls on sales to China and other restricted jurisdictions.
- Inventory Levels: Review inventory write-down risks given the $7.3 million increase in inventory YTD and the company's history of write-downs for excess/obsolete stock.
- Share Repurchase Program: Track the remaining $35 million authorization and the company's ability to continue buybacks given the negative operating cash flow.